2018
This study revealed that Selank works as a positive allosteric modulator of GABA receptors, meaning it makes your brain's natural calming system respond more strongly without directly switching it on the way benzodiazepines (anti-anxiety drugs like Xanax) do. This explains why Selank reduces anxiety without causing sedation, dependence, or memory problems.
Vyunova TV, Andreeva L, Shevchenko K, et al.
2019
Selank prevented alcohol-induced memory problems in rats by protecting BDNF (brain-derived neurotrophic factor, a protein that helps brain cells grow and connect) levels in the hippocampus (a memory center) and prefrontal cortex (the front thinking area). This shows Selank's potential for protecting brain function and supporting healthy memory formation.
Kolik LG, Nadorova AV, Antipova TA, et al.
2014
In patients with anxiety disorders, Selank showed anti-anxiety effects comparable to phenazepam (a strong benzodiazepine) but with significantly better tolerability. Importantly, Selank's anti-anxiety effects lasted for a week after stopping the peptide, suggesting lasting benefits.
Medvedev VE, Tereshchenko ON, Israelian AIu, et al.
2011
Selank significantly changed the activity of 34 genes involved in inflammation, including the important Bcl6 gene crucial for immune system development. This demonstrates Selank's immune-adjusting effects beyond just brain benefits.
Kolomin T, Shadrina M, Andreeva L, et al.
2008
In patients with generalized anxiety disorder and neurasthenia (a condition of mental and physical fatigue), Selank regulated the balance of Th1/Th2 cytokines (two types of immune messengers) and affected IL-6 levels. The study suggests Selank could work as an immunomodulator (something that adjusts the immune system) for people with anxiety disorders, potentially helping both mind and immune system.
Uchakina ON, Uchakin PN, Miasoedov NF, et al.
2001
Patients with generalized anxiety showed a shortened enkephalin half-life (enkephalins are natural painkiller-like peptides) and reduced total enkephalinase activity (activity of the enzymes that break them down) in blood. Selank inhibited the enzymatic breakdown of enkephalin in plasma (IC50 15 microM; IC50 is the amount needed to block half the activity), more strongly than the peptidase inhibitors bacitracin and puromycin. The authors proposed that slowing enkephalin breakdown is one mechanism behind Selank's anti-anxiety effect.
Zozulya AA, Kost NV, Sokolov OY, et al.
2009
The registered product is a 0.15% nasal drop solution (1.5 mg/mL; one drop delivers 75 mcg). The approved dose is 2 drops in each nostril three times a day, which is 4 drops, or 300 mcg, per dose, so 900 mcg a day. It is given for a 14-day course, repeatable after 1-3 weeks on a doctor's advice. About 92.8% of the dose gets into the bloodstream through the nose (absolute bioavailability), and the peptide can be detected in blood plasma within 30 seconds. No cases of overdose have been recorded.
Ministry of Health of the Russian Federation; JSC Peptogen (registration holder)
2011
A single dose of Selank changed the activity of chemokine, cytokine, and receptor genes (immune messenger genes) in mouse spleen at 6 and 24 hours. Most of the same gene changes occurred after giving the dipeptide Gly-Pro (two amino acids) on its own. The authors state this had earlier been identified as Selank's pharmacophore, the smallest fragment that carries antiviral activity.
Kolomin TA, Shadrina MI, Slominsky PA, et al.
2008
In 62 people with generalised anxiety disorder or neurasthenia (30 on selank, 32 on medazepam), selank's anti-anxiety effect was similar to the benzodiazepine medazepam on the Hamilton, Zung and CGI scales (standard symptom rating scales), and selank additionally reduced fatigue where medazepam did not. The developing institute's monograph records the doses as selank 2,700 mcg a day against medazepam 30 mg a day, over 14 days.
Zozulya AA, Neznamov GG, Syunyakov TS, et al.